Loading...
•
Mar 31, 2023
Amphastar Q1 2023 Earnings Report
Amphastar's Q1 2023 financial performance was marked by increased net revenues and net income compared to the same period last year, driven by strong sales of key products and strategic portfolio expansions.
Key Takeaways
Amphastar Pharmaceuticals reported a strong first quarter in 2023, with net revenues reaching $140.0 million, a 16% increase compared to Q1 2022. GAAP net income rose to $26.0 million, or $0.50 per share, and adjusted non-GAAP net income was $32.1 million, or $0.62 per share. The company's growth was primarily fueled by increased sales of glucagon, Primatene MIST®, and epinephrine.
Net revenues increased by 16% to $140.0 million, driven by strong sales of glucagon, Primatene MIST®, and epinephrine.
GAAP net income increased to $26.0 million, or $0.50 per share.
Adjusted non-GAAP net income increased to $32.1 million, or $0.62 per share.
The company expects growth trends in key products to continue and anticipates further contributions from newly launched products and acquisitions.
Revenue by Segment
Forward Guidance
The company expects similar growth trends in key products to continue and believes newly-launched regadenoson and the approval of intranasal naloxone will add another layer to its complex generics and proprietary products portfolio.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...